

GoodRx Holdings, Inc. (GDRX)

Nasdaq; business equipment; SIC 7374, Services-Computer Processing & Data Preparation; CIK 0001809519

GoodRx Holdings, Inc. GDRX; business equipment					
Grade	D/E	A B C D E on the D/E boundary of 497 graded peers percentile 77.8; sampling error 2.2 points; lower is stronger			
Rank	387 of 497				
Profitability	C	percentile 52.5			
Solvency	C	percentile 54.7			
Growth and financing	D	percentile 73.3			
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025				
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025				
Size band	\$591M to \$2.67B assets total assets \$1.4B				
Standard universe	inside revenue above \$1M and assets above \$10M				
Warnings	none active not computable: dilution, distress				
Inputs computable	9 of 14				
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026				
Last close	\$3.38 2026-10-08; market equity \$0				
Price used in grade	None				

D/E, the sloth

on the D/E boundary of its sector; letters are fifths of the 497 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it

Rescans on file: C from Mar 21, 2025, D/E from Mar 21, 2026, D from Apr 21,

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Our mission is to help Americans save time and money when filling their medications. To achieve this, we are building the leading, consumer-focused digital healthcare platform in the United States. GoodRx was founded to solve the challenges that consumers face in understanding, accessing, and affording healthcare by removing the friction and inefficiencies in the system. We started with a price comparison tool for prescriptions, offering consumers free access to lower prices on their medication.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 52.5						
Gross profitability		not computable	28.5%			one or more required annual facts are missing
Return on invested capital		5.8%	10.9%	63.0	136	2025-12-31
Accruals ratio		(9.8%)	(7.4%)	42.1	621	2025-12-31
Gross margin stability, five years		not computable	2.4 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 54.7						
Twelve-month failure probability		not computable	0.05%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		(0.18)	2.18	59.3	566	2025-12-31
Net debt to EBITDA		2.54x	1.11x	68.5	147	2025-12-31
Interest coverage		not computable	3.77x			one or more required annual facts are missing
Current ratio		2.61x	2.02x	36.2	666	2025-12-31
Growth and financing, sleeve percentile 73.3						
Revenue growth, three-year compound		1.3%	6.4%	64.1	538	2025-12-31
Free cash flow growth, three-year compound		4.8%	17.2%	68.5	268	2025-12-31
Reinvestment rate		(294.9%)	14.3%	88.9	226	2025-12-31
Asset growth, three years		(4.4%)	5.0%	71.9	563	2025-12-31
Net share issuance, one year		not computable	0.5%			two annual share counts are required; found 0

Among 497 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
382	Marchex Inc. (MCHX)	76.8	D	
383	Harvard Bioscience Inc. (HBIO)	77.0	D	
384	Synopsys Inc. (SNPS)	77.2	D	

385	Duos Technologies Group, Inc. (DUOT)	77.4	D	dilution, late filer, fortress balance sheet
386	Spectrum Brands Holdings, Inc. (SPB)	77.6	D	
387	GoodRx Holdings, Inc. (GDRX) <	77.8	D/E	
388	Thermo Fisher Scientific Inc. (TMO)	78.0	D/E	
389	Asure Software Inc. (ASUR)	78.2	D/E	
390	Clarivate plc (CLVT)	78.4	D/E	
391	SmartRent, Inc. (SMRT)	78.6	D/E	
392	Immersion Corp. (IMMR)	78.8	D/E	late filer, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(17.5%)	2.2%	32
Distance from 52-week high	(27.6%)	(30.0%)	53
EBIT to enterprise value	not computable	1.5%	
Free cash flow yield	not computable	2.7%	
Book value to price	not computable	0.23	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	3.9%	
Relative strength against the sector, log excess return	(0.48)	(0.26)	32

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$296.1M
Operating cash flow, four quarters	\$201.6M
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$3.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	\$87.5M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$56.5M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
3	income tax	us-gaap:IncomeTaxExpenseBenefit	\$26.1M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
4	total debt	us-gaap:LongTermDebt	\$495.0M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
5	book equity	us-gaap:StockholdersEquity	\$616.3M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$261.8M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
7	total debt	us-gaap:LongTermDebt	\$500.0M	2024-12-31	2025-02-27	10-K	0001809519-25-000040
8	book equity	us-gaap:StockholdersEquity	\$724.7M	2024-12-31	2026-02-26	10-K	0001809519-26-000031
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$448.3M	2024-12-31	2026-02-26	10-K	0001809519-26-000031

10	net income	us-gaap:NetIncomeLoss	\$30.4M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$167.9M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
12	assets	us-gaap:Assets	\$1.4B	2025-12-31	2026-02-26	10-K	0001809519-26-000031
13	assets	us-gaap:Assets	\$1.4B	2024-12-31	2026-02-26	10-K	0001809519-26-000031
14	current assets	us-gaap:AssetsCurrent	\$643.1M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
15	current liabilities	us-gaap:LiabilitiesCurrent	\$246.0M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.4B	2025-12-31	2026-02-26	10-K	0001809519-26-000031
17	liabilities	us-gaap:Liabilities	\$787.8M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
18	depreciation amortization	us-gaap:Depreciation	\$4.2M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$796.9M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$792.3M	2024-12-31	2026-02-26	10-K	0001809519-26-000031
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$750.3M	2023-12-31	2026-02-26	10-K	0001809519-26-000031
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$766.6M	2022-12-31	2025-02-27	10-K	0001809519-25-000040
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.5M	2025-12-31	2026-02-26	10-K	0001809519-26-000031
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$183.9M	2024-12-31	2026-02-26	10-K	0001809519-26-000031
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.2M	2024-12-31	2026-02-26	10-K	0001809519-26-000031
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$138.3M	2023-12-31	2026-02-26	10-K	0001809519-26-000031
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.0M	2023-12-31	2026-02-26	10-K	0001809519-26-000031
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$146.8M	2022-12-31	2025-02-27	10-K	0001809519-25-000040
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.0M	2022-12-31	2025-02-27	10-K	0001809519-25-000040
30	current assets	us-gaap:AssetsCurrent	\$659.3M	2024-12-31	2026-02-26	10-K	0001809519-26-000031
31	current liabilities	us-gaap:LiabilitiesCurrent	\$123.9M	2024-12-31	2026-02-26	10-K	0001809519-26-000031
32	assets	us-gaap:Assets	\$1.6B	2023-12-31	2025-02-27	10-K	0001809519-25-000040
33	assets	us-gaap:Assets	\$1.6B	2022-12-31	2024-02-29	10-K	0001809519-24-000032